Search research articles
Contact Us
Filters
Showing results (261-270 of 288) with videos related to
Page
of 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, et al.
The Lancet. Oncology
|
September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing, Deborah J Wong, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2015
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik, S Peter Kang, Drew Rasco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Kyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
Timothy A Yap, Li Yan, Amita Patnaik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Amita Patnaik, Paul Haluska, Anthony W Tolcher, et al.
Cancer
|
March 14, 2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
Glenwood D Goss, Everett E Vokes, Michael S Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 7, 2022
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
Timothy A Yap, Patricia M LoRusso, Deborah J Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEK
Anthony W Tolcher, Khurum Khan, Michael Ong, et al.
Page
of 29
Search research articles
Search
Showing results (261-270 of 288) with videos related to
Sort By:
Page
of 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, et al.
The Lancet. Oncology
|
September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing, Deborah J Wong, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2015
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik, S Peter Kang, Drew Rasco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Kyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
Timothy A Yap, Li Yan, Amita Patnaik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Amita Patnaik, Paul Haluska, Anthony W Tolcher, et al.
Cancer
|
March 14, 2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
Glenwood D Goss, Everett E Vokes, Michael S Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 7, 2022
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
Timothy A Yap, Patricia M LoRusso, Deborah J Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEK
Anthony W Tolcher, Khurum Khan, Michael Ong, et al.
Page
of 29